SCHEMBL7510360

SCHEMBL7510360

C[SiH](C)N(C1c2ccccc2-c2ccccc21)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.50
SLC22A2 O15244 1/20 0.41
SLC22A3 O75751 1/20 0.41
KMT2A Q03164 2/20 0.33
HTR2A P28223 1/20 0.32
POLB P06746 2/20 0.32
ACHE P22303 2/20 0.31
CHRM2 P08172 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD1 P21728 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
ADRA1A P35348 1/20 0.31
OPRM1 P35372 1/20 0.31
DRD3 P35462 1/20 0.31
SLC6A3 Q01959 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7630742 0.84 GPR3 (0.39) GPR3SLC22A2SLC22A3
SCHEMBL4375149 0.80 GPR3 (0.36) GPR3SLC22A2SLC22A3
SCHEMBL7629468 0.74 GPR3 (0.32) GPR3
Hydrochloric Acid SCHEMBL4873948 0.72 GPR3 (0.44) GPR3SLC22A2SLC22A3
Hydrochloric Acid SCHEMBL4880315 0.72 GPR3 (0.44) GPR3SLC22A2SLC22A3
Hydrochloric Acid SCHEMBL4872846 0.72 GPR3 (0.44) GPR3SLC22A2SLC22A3
SCHEMBL1477602 0.71 GPR3 (0.64) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL7634050 0.71
Hydrochloric Acid SCHEMBL673076 0.68 GPR3 (0.36) GPR3SLC22A2SLC22A3
SCHEMBL1509312 0.68 GPR3 (1.00) GPR3SLC22A2SLC22A3KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070072-A4 SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS BOULDER SCIENT CO (US) 2002-09-25 EP disclosed
EP-1150986-A4 SILYL AMINES BOULDER SCIENT CO (US) 2002-08-07 EP disclosed
US-6410767-B2 USING N-SILYLATED MONO(CYCLOPENTADIENYL) LIGAND BOULDER SCIENTIFIC CO. 2002-06-25 US disclosed
US-20010056199-A1 Silylated and N-silylated compound synthesis BOULDER SCIENTIFIC COMPANY 2001-12-27 US disclosed
EP-1150986-A1 SILYL AMINES BOULDER SCIENTIFIC COMPANY (US) 2001-11-07 EP disclosed
WO-2001038334-A1 SILYL AMINES BOULDER SCIENTIFIC COMPANY (US) 2001-05-31 WO disclosed
US-6180810-B1 SILYL AMINES WHICH BOND COVALENTLY TO METAL CENTER OF COMPLEX TO PROVIDE OLEFIN POLYMERIZATION CATALYST COMPONENT BOULDER SCIENTIFIC COMPANY 2001-01-30 US disclosed
EP-1070072-A1 SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS BOULDER SCIENTIFIC COMPANY (US) 2001-01-24 EP disclosed
WO-2000047587-A1 SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS BOULDER SCIENTIFIC COMPANY (US) 2000-08-17 WO disclosed
US-6087518-A Silylated and N-silylated compound synthesis BOULDER SCIENTIFIC COMPANY (US) 2000-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056199-A1 Silylated and N-silylated compound synthesis LSS, NCL, FNTA GPR3 2349/4885SLC22A2 4192/4885SLC22A3 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.